{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:54Z","timestamp":1786982754100,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T00:00:00Z","timestamp":1550534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s40263-019-00607-5","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T00:18:51Z","timestamp":1550535531000},"page":"283-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy"],"prefix":"10.1007","volume":"33","author":[{"given":"Zeinab","family":"Gharaylou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Tafakhori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmira","family":"Agah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vajihe","family":"Aghamollaii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Kebriaeezadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoudreza","family":"Hadjighassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,19]]},"reference":[{"issue":"5","key":"607_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrn3482","volume":"14","author":"EM Goldberg","year":"2013","unstructured":"Goldberg EM, Coulter DA. Mechanisms of epileptogenesis: a convergence on neural circuit dysfunction. Nat Rev Neurosci. 2013;14(5):337\u201349.","journal-title":"Nat Rev Neurosci"},{"issue":"48","key":"607_CR2","doi-asserted-by":"publisher","first-page":"40224","DOI":"10.1074\/jbc.R112.386664","volume":"287","author":"E Sigel","year":"2012","unstructured":"Sigel E, Steinmann ME. Structure, function, and modulation of GABA(A) receptors. J Biol Chem. 2012;287(48):40224\u201331.","journal-title":"J Biol Chem"},{"issue":"9","key":"607_CR3","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/ncpneuro0883","volume":"4","author":"KT Kahle","year":"2008","unstructured":"Kahle KT, Staley KJ, Nahed BV, Gamba G, Hebert SC, Lifton RP, et al. Roles of the cation\u2013chloride cotransporters in neurological disease. Nat Clin Pract Neurol. 2008;4(9):490\u2013503.","journal-title":"Nat Clin Pract Neurol"},{"key":"607_CR4","first-page":"309","volume":"15","author":"E Delpire","year":"2000","unstructured":"Delpire E. Cation\u2013chloride cotransporters in neuronal communication. News Physiol Sci. 2000;15:309\u201312.","journal-title":"News Physiol Sci"},{"issue":"4","key":"607_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/epi.13670","volume":"58","author":"RS Fisher","year":"2017","unstructured":"Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):522\u201330.","journal-title":"Epilepsia"},{"key":"607_CR6","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.wneu.2016.12.074","volume":"99","author":"AA Asadi-Pooya","year":"2017","unstructured":"Asadi-Pooya AA, Stewart GR, Abrams DJ, Sharan A. Prevalence and incidence of drug-resistant mesial temporal lobe epilepsy in the United States. World Neurosurg. 2017;99:662\u20136.","journal-title":"World Neurosurg"},{"issue":"1","key":"607_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41598-017-00196-7","volume":"7","author":"L Chen","year":"2017","unstructured":"Chen L, Wan L, Wu Z, Ren W, Huang Y, Qian B, et al. KCC2 downregulation facilitates epileptic seizures. Sci Rep. 2017;7(1):156.","journal-title":"Sci Rep"},{"issue":"5597","key":"607_CR8","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1126\/science.1076510","volume":"298","author":"I Cohen","year":"2002","unstructured":"Cohen I, Navarro V, Clemenceau S, Baulac M, Miles R. On the origin of interictal activity in human temporal lobe epilepsy in vitro. Science. 2002;298(5597):1418\u201321.","journal-title":"Science"},{"issue":"37","key":"607_CR9","doi-asserted-by":"publisher","first-page":"9866","DOI":"10.1523\/JNEUROSCI.2761-07.2007","volume":"27","author":"G Huberfeld","year":"2007","unstructured":"Huberfeld G, Wittner L, Clemenceau S, Baulac M, Kaila K, Miles R, et al. Perturbed chloride homeostasis and GABAergic signaling in human temporal lobe epilepsy. J Neurosci. 2007;27(37):9866\u201373.","journal-title":"J Neurosci"},{"issue":"51","key":"607_CR10","doi-asserted-by":"publisher","first-page":"14012","DOI":"10.1523\/JNEUROSCI.4390-07.2007","volume":"27","author":"HR Pathak","year":"2007","unstructured":"Pathak HR, Weissinger F, Terunuma M, Carlson GC, Hsu FC, Moss SJ, et al. Disrupted dentate granule cell chloride regulation enhances synaptic excitability during development of temporal lobe epilepsy. J Neurosci. 2007;27(51):14012\u201322.","journal-title":"J Neurosci"},{"key":"607_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.brainres.2008.04.047","volume":"1221","author":"X Li","year":"2008","unstructured":"Li X, Zhou J, Chen Z, Chen S, Zhu F, Zhou L. Long-term expressional changes of Na+\u2013K+\u2013Cl\u2212 co-transporter 1 (NKCC1) and K+\u2013Cl\u2212 co-transporter 2 (KCC2) in CA1 region of hippocampus following lithium-pilocarpine induced status epilepticus (PISE). Brain Res. 2008;1221:141\u20136.","journal-title":"Brain Res"},{"issue":"2\u20133","key":"607_CR12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.eplepsyres.2007.01.004","volume":"74","author":"A Sen","year":"2007","unstructured":"Sen A, Martinian L, Nikolic M, Walker MC, Thom M, Sisodiya SM. Increased NKCC1 expression in refractory human epilepsy. Epilepsy Res. 2007;74(2\u20133):220\u20137.","journal-title":"Epilepsy Res"},{"issue":"10","key":"607_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrn3819","volume":"15","author":"K Kaila","year":"2014","unstructured":"Kaila K, Price TJ, Payne JA, Puskarjov M, Voipio J. Cation\u2013chloride cotransporters in neuronal development, plasticity and disease. Nat Rev Neurosci. 2014;15(10):637\u201354.","journal-title":"Nat Rev Neurosci"},{"issue":"25","key":"607_CR14","doi-asserted-by":"publisher","first-page":"8602","DOI":"10.1523\/JNEUROSCI.0633-10.2010","volume":"30","author":"C Brandt","year":"2010","unstructured":"Brandt C, Nozadze M, Heuchert N, Rattka M, Loscher W. Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy. J Neurosci. 2010;30(25):8602\u201312.","journal-title":"J Neurosci"},{"key":"607_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.neuropharm.2012.05.045","volume":"69","author":"W Loscher","year":"2013","unstructured":"Loscher W, Puskarjov M, Kaila K. Cation\u2013chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments. Neuropharmacology. 2013;69:62\u201374.","journal-title":"Neuropharmacology"},{"issue":"3","key":"607_CR16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/jcph.596","volume":"56","author":"V Jullien","year":"2016","unstructured":"Jullien V, Pressler RM, Boylan G, Blennow M, Marlow N, Chiron C, et al. Pilot evaluation of the population pharmacokinetics of bumetanide in term newborn infants with seizures. J Clin Pharmacol. 2016;56(3):284\u201390.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"607_CR17","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1177\/0883073809333526","volume":"24","author":"KT Kahle","year":"2009","unstructured":"Kahle KT, Barnett SM, Sassower KC, Staley KJ. Decreased seizure activity in a human neonate treated with bumetanide, an inhibitor of the Na(+)\u2013K(+)\u20132Cl(\u2212) cotransporter NKCC1. J Child Neurol. 2009;24(5):572\u20136.","journal-title":"J Child Neurol"},{"issue":"5","key":"607_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S1474-4422(14)70303-5","volume":"14","author":"RM Pressler","year":"2015","unstructured":"Pressler RM, Boylan GB, Marlow N, Blennow M, Chiron C, Cross JH, et al. Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1\/2 trial. Lancet Neurol. 2015;14(5):469\u201377.","journal-title":"Lancet Neurol"},{"issue":"1","key":"607_CR19","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1111\/j.1528-1167.2012.03654.x","volume":"54","author":"S Eftekhari","year":"2013","unstructured":"Eftekhari S, Mehvari Habibabadi J, Najafi Ziarani M, Hashemi Fesharaki SS, Gharakhani M, Mostafavi H, et al. Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy. Epilepsia. 2013;54(1):e9\u201312.","journal-title":"Epilepsia"},{"issue":"4","key":"607_CR20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","volume":"58","author":"IE Scheffer","year":"2017","unstructured":"Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512\u201321.","journal-title":"Epilepsia"},{"issue":"6","key":"607_CR21","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"P Kwan","year":"2010","unstructured":"Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069\u201377.","journal-title":"Epilepsia"},{"issue":"8","key":"607_CR22","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/jps.2600730821","volume":"73","author":"AA Halazo","year":"1984","unstructured":"Halazo AA, Colburn WA, Gustafson JH, Young RL, Parsonnet M. Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. J Pharm Sci. 1984;73(8):1108\u201313.","journal-title":"J Pharm Sci"},{"issue":"6","key":"607_CR23","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/epi.12620","volume":"55","author":"M Puskarjov","year":"2014","unstructured":"Puskarjov M, Kahle KT, Ruusuvuori E, Kaila K. Pharmacotherapeutic targeting of cation\u2013chloride cotransporters in neonatal seizures. Epilepsia. 2014;55(6):806\u201318.","journal-title":"Epilepsia"},{"key":"607_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejphar.2014.11.019","volume":"746","author":"K Tollner","year":"2015","unstructured":"Tollner K, Brandt C, Romermann K, Loscher W. The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide. Eur J Pharmacol. 2015;746:167\u201373.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"607_CR25","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/jphp.12341","volume":"67","author":"MD Donovan","year":"2015","unstructured":"Donovan MD, O\u2019Brien FE, Boylan GB, Cryan JF, Griffin BT. The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: an integrated in vivo microdialysis study in the rat. J Pharm Pharmacol. 2015;67(4):501\u201310.","journal-title":"J Pharm Pharmacol"},{"key":"607_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.neuropharm.2016.04.029","volume":"108","author":"MR Kelley","year":"2016","unstructured":"Kelley MR, Deeb TZ, Brandon NJ, Dunlop J, Davies PA, Moss SJ. Compromising KCC2 transporter activity enhances the development of continuous seizure activity. Neuropharmacology. 2016;108:103\u201310.","journal-title":"Neuropharmacology"},{"issue":"4","key":"607_CR27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/j.1528-1167.2007.00986.x","volume":"48","author":"A Munoz","year":"2007","unstructured":"Munoz A, Mendez P, DeFelipe J, Alvarez-Leefmans FJ. Cation\u2013chloride cotransporters and GABA-ergic innervation in the human epileptic hippocampus. Epilepsia. 2007;48(4):663\u201373.","journal-title":"Epilepsia"},{"issue":"6","key":"607_CR28","first-page":"561","volume":"8","author":"X Cai","year":"2013","unstructured":"Cai X, Yang L, Zhou J, Zhu D, Guo Q, Chen Z, et al. Anomalous expression of chloride transporters in the sclerosed hippocampus of mesial temporal lobe epilepsy patients. Neural Regen Res. 2013;8(6):561\u20138.","journal-title":"Neural Regen Res"},{"issue":"22","key":"607_CR29","doi-asserted-by":"publisher","first-page":"8465","DOI":"10.1073\/pnas.0602979103","volume":"103","author":"E Palma","year":"2006","unstructured":"Palma E, Amici M, Sobrero F, Spinelli G, Di Angelantonio S, Ragozzino D, et al. Anomalous levels of Cl\u2212 transporters in the hippocampal subiculum from temporal lobe epilepsy patients make GABA excitatory. Proc Natl Acad Sci. 2006;103(22):8465\u20138.","journal-title":"Proc Natl Acad Sci"},{"key":"607_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1146\/annurev.physiol.64.081501.155847","volume":"64","author":"E Delpire","year":"2002","unstructured":"Delpire E, Mount DB. Human and murine phenotypes associated with defects in cation\u2013chloride cotransport. Annu Rev Physiol. 2002;64:803\u201343.","journal-title":"Annu Rev Physiol"}],"updated-by":[{"DOI":"10.1007\/s40263-019-00653-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T00:00:00Z","timestamp":1563840000000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-019-00607-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00607-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00607-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T05:55:00Z","timestamp":1585893300000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-019-00607-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,19]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["607"],"URL":"https:\/\/doi.org\/10.1007\/s40263-019-00607-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,19]]},"assertion":[{"value":"19 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Zeinab Gharaylou, Abbas Tafakhori, Elmira Agah, Vajihe Aghamollaii, Abbas Kebriaeezadeh and  Mahmoudreza Hadjighassem declare that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Ethics Committee of Tehran University of Medical Sciences approved this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all study participants prior to commencement of this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}]}}